{"title":"Transcatheter edge-to-edge mitral valve repair for severe heart failure in a young woman with polymyositis: A case report","authors":"Masayoshi Fujii MD, Tetsuari Onishi MD, PhD, Hiroyuki Yamamoto MD, PhD, Nobuyuki Takahashi MD, Tomofumi Takaya MD, PhD, Hiroya Kawai MD, PhD, FJCC","doi":"10.1016/j.jccase.2024.06.001","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Polymyositis (PM) and </span>dermatomyositis (DM) are chronic inflammatory muscle disorders characterized by </span>muscle weakness and fatigue. They are histopathologically defined by </span>inflammatory cell<span><span> infiltrates in the skeletal muscle<span>. In a recent meta-analysis, the incidence of cardiovascular complications in patients with PM/DM ranged from 9 to 72 %, with heart failure being the most commonly reported heart disease. In cases of heart failure accompanied by severe </span></span>mitral regurgitation<span> that is refractory due to guideline-directed medical therapy, the transcatheter edge-to-edge mitral valve repair (TEER) procedure using the MitraClip (Abbott Vascular, Santa Clara, CA, USA) offers an alternative therapeutic approach. We present a pioneering case report describing the successful application of TEER in a young woman with drug-refractory heart failure due to cardiovascular involvement in PM.</span></span></p></div><div><h3>Learning objective</h3><p></p><ul><li><span>•</span><span><p><span>In polymyositis (PM)/ dermatomyositis (DM), the most commonly reported clinical heart disorder is heart failure, with some cases attributed to </span>mitral regurgitation.</p></span></li><li><span>•</span><span><p>Patients suffering from systemic inflammatory diseases such as PM/DM often face high surgical risk, and the MitraClip is an effective treatment modality.</p></span></li></ul></div>","PeriodicalId":52092,"journal":{"name":"Journal of Cardiology Cases","volume":"30 3","pages":"Pages 90-93"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiology Cases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878540924000574","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Polymyositis (PM) and dermatomyositis (DM) are chronic inflammatory muscle disorders characterized by muscle weakness and fatigue. They are histopathologically defined by inflammatory cell infiltrates in the skeletal muscle. In a recent meta-analysis, the incidence of cardiovascular complications in patients with PM/DM ranged from 9 to 72 %, with heart failure being the most commonly reported heart disease. In cases of heart failure accompanied by severe mitral regurgitation that is refractory due to guideline-directed medical therapy, the transcatheter edge-to-edge mitral valve repair (TEER) procedure using the MitraClip (Abbott Vascular, Santa Clara, CA, USA) offers an alternative therapeutic approach. We present a pioneering case report describing the successful application of TEER in a young woman with drug-refractory heart failure due to cardiovascular involvement in PM.
Learning objective
•
In polymyositis (PM)/ dermatomyositis (DM), the most commonly reported clinical heart disorder is heart failure, with some cases attributed to mitral regurgitation.
•
Patients suffering from systemic inflammatory diseases such as PM/DM often face high surgical risk, and the MitraClip is an effective treatment modality.